FF Pharma will focus on the development of novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases
FF Pharma will focus on the development of novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. The company's lead product, FFP102, is a clinical stage humanized anti-CD40 monoclonal antibody.